Lilly says Trulicity cut risk of CV events in wide patient group
Lilly says its once-weekly diabetes drug Trulicity cut major adverse cardiovascular events (MACE) in patients taking part in the REWIND trial.
Read More
Tag: REWIND
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
